Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodrigo E Mendes

Showing results (11-20 of 278) with videos related to

Pageof 28
Sort By:
International Journal of Antimicrobial Agents|July 6, 2010
Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008)Rodrigo E Mendes, Helio S Sader, Ronald N Jones
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 20, 2021
Antimicrobial activity of dalbavancin and comparators against Staphylococcus aureus causing pneumonia in patients with and without cystic fibrosisHelio S Sader, Leonard R Duncan, Rodrigo E Mendes
Diagnostic Microbiology and Infectious Disease|September 25, 2020
Update on the in vitro activity of dalbavancin against indicated species (Staphylococcus aureus, Enterococcus faecalis, β-hemolytic streptococci, and Streptococcus anginosus group) collected from United States hospitals in 2017-2019Helio S Sader, Jennifer M Streit, Rodrigo E Mendes
Journal of Clinical Microbiology|June 13, 2014
Quality control MIC ranges used for telavancin with application of a revised CLSI reference broth microdilution methodJames E Ross, Rodrigo E Mendes, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|August 10, 2016
Reproducibility of dalbavancin MIC test results and an updated surrogate accuracy analysis of vancomycin MIC values to infer dalbavancin susceptibility (2014)Ronald N Jones, Paul R Rhomberg, Rodrigo E Mendes
Antimicrobial Agents and Chemotherapy|March 23, 2016
Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014)Ronald N Jones, Jason E Schuchert, Rodrigo E Mendes
The Journal of Antimicrobial Chemotherapy|December 1, 2021
In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized β-lactamase genesRodrigo E Mendes, Paul R Rhomberg, Amy A Watters, et al.
The Journal of Antimicrobial Chemotherapy|July 31, 2018
Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17)Helio S Sader, Mariana Castanheira, Rodrigo E Mendes, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|August 19, 2008
Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007)Mariana Castanheira, Rodrigo E Mendes, Paul R Rhomberg, et al.
Diagnostic Microbiology and Infectious Disease|November 22, 2008
United States resistance surveillance results for linezolid (LEADER Program for 2007)Ronald N Jones, James E Ross, Mariana Castanheira, et al.
Pageof 28

Showing results (11-20 of 278) with videos related to

Sort By:
Pageof 28
International Journal of Antimicrobial Agents|July 6, 2010
Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008)Rodrigo E Mendes, Helio S Sader, Ronald N Jones
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 20, 2021
Antimicrobial activity of dalbavancin and comparators against Staphylococcus aureus causing pneumonia in patients with and without cystic fibrosisHelio S Sader, Leonard R Duncan, Rodrigo E Mendes
Diagnostic Microbiology and Infectious Disease|September 25, 2020
Update on the in vitro activity of dalbavancin against indicated species (Staphylococcus aureus, Enterococcus faecalis, β-hemolytic streptococci, and Streptococcus anginosus group) collected from United States hospitals in 2017-2019Helio S Sader, Jennifer M Streit, Rodrigo E Mendes
Journal of Clinical Microbiology|June 13, 2014
Quality control MIC ranges used for telavancin with application of a revised CLSI reference broth microdilution methodJames E Ross, Rodrigo E Mendes, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|August 10, 2016
Reproducibility of dalbavancin MIC test results and an updated surrogate accuracy analysis of vancomycin MIC values to infer dalbavancin susceptibility (2014)Ronald N Jones, Paul R Rhomberg, Rodrigo E Mendes
Antimicrobial Agents and Chemotherapy|March 23, 2016
Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014)Ronald N Jones, Jason E Schuchert, Rodrigo E Mendes
The Journal of Antimicrobial Chemotherapy|December 1, 2021
In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized β-lactamase genesRodrigo E Mendes, Paul R Rhomberg, Amy A Watters, et al.
The Journal of Antimicrobial Chemotherapy|July 31, 2018
Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17)Helio S Sader, Mariana Castanheira, Rodrigo E Mendes, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|August 19, 2008
Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007)Mariana Castanheira, Rodrigo E Mendes, Paul R Rhomberg, et al.
Diagnostic Microbiology and Infectious Disease|November 22, 2008
United States resistance surveillance results for linezolid (LEADER Program for 2007)Ronald N Jones, James E Ross, Mariana Castanheira, et al.
Pageof 28